Database : MEDLINE
Search on : Penile and Neoplasms [Words]
References found : 6011 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 602 go to page                         

  1 / 6011 MEDLINE  
              next record last record
select
to print
Photocopy

[PMID]: 29376611
[Au] Autor:Epifanova MV; Chalyi ME; Gvasaliya BR; Eremin II; Pulin AA; Nadelyaeva II; Artemenko SA; Galitskaya DA; Repin AM
[Ad] Address:Research Institute for Uronephrology and Human Reproductive Health, Moscow, Russia.
[Ti] Title:[New approaches for recovery of erectile function in patients after radical prostatectomy].
[So] Source:Urologiia;(6):138-143, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:Prostate cancer (PCa) is one of the most common maligmancies and causes of death among men. Radical prostatectomy (RP) is optimal and recommended treatment modality for localized prostate cancer. More than half of all men undergoing surgery experience problems with erectile function and existing treatments do not provide a positive effect. Thus, there is a need for new approaches to the restoration of erectile function in patients after RP. One of these is the use of cell technologies, namely the stromal-vascular fraction and autologous platelet-rich plasma. This review examines the results of preclinical and clinical studies investigating the efficacy and safety of these treatment options in erectile dysfunction.
[Mh] MeSH terms primary: Erectile Dysfunction
Penile Erection
Postoperative Complications/therapy
Prostatectomy/adverse effects
Prostatic Neoplasms/surgery
Recovery of Function
[Mh] MeSH terms secundary: Erectile Dysfunction/etiology
Erectile Dysfunction/therapy
Humans
Male
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  2 / 6011 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28463150
[Au] Autor:Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; Michalski JM; Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium
[Ad] Address:Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: hiramgay@wustl.edu.
[Ti] Title:External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):304-317, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: The long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2 years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer. METHODS AND MATERIALS: We analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy. HRQOL was measured using the expanded prostate cancer index composite 26-item questionnaire at 2, 6, 12, and 24 months after the initiation of NADT. We used the χ or Fisher exact test to compare the shift in percentages between groups that did or did not receive NADT. Analyses were conducted at the 2-sided 5% significance level. RESULTS: For subjects receiving EBRT, questions regarding the ability to have an erection, ability to reach an orgasm, quality of erections, frequency of erections, ability to function sexually, and lack of energy were in a significantly worse dichotomized category for the patients receiving NADT. Comparing the baseline versus 24-month outcomes, 24%, 23%, and 30% of participants receiving EBRT plus NADT shifted to the worse dichotomized category for the ability to reach an orgasm, quality of erections, and ability to function sexually compared with 14%, 13%, and 16% in the EBRT group, respectively. CONCLUSIONS: Compared with baseline, at 2 years, participants receiving NADT plus EBRT compared with EBRT alone had worse HRQOL, as measured by the ability to reach orgasm, quality of erections, and ability to function sexually. However, no difference was found in the ability to have an erection, frequency of erections, overall sexual function, hot flashes, breast tenderness/enlargement, depression, lack of energy, or change in body weight. The improved survival in intermediate- and high-risk patients receiving NADT and EBRT necessitates pretreatment counseling of the HRQOL effect of NADT and EBRT.
[Mh] MeSH terms primary: Androgen Antagonists/adverse effects
Brachytherapy/adverse effects
Neoadjuvant Therapy/adverse effects
Orgasm
Penile Erection
Prostatic Neoplasms/therapy
Quality of Life
[Mh] MeSH terms secundary: Aged
Aged, 80 and over
Androgen Antagonists/therapeutic use
Body Weight/drug effects
Body Weight/radiation effects
Brachytherapy/methods
Brachytherapy/statistics & numerical data
Breast/drug effects
Breast/radiation effects
Chi-Square Distribution
Combined Modality Therapy/adverse effects
Combined Modality Therapy/methods
Combined Modality Therapy/statistics & numerical data
Depression/etiology
Erectile Dysfunction/etiology
Fatigue/etiology
Hot Flashes/etiology
Humans
Male
Middle Aged
Neoadjuvant Therapy/methods
Neoadjuvant Therapy/statistics & numerical data
Orgasm/drug effects
Orgasm/radiation effects
Penile Erection/drug effects
Penile Erection/radiation effects
Prospective Studies
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood
Prostatic Neoplasms/pathology
Surveys and Questionnaires
Time Factors
[Pt] Publication type:JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Name of substance:0 (Androgen Antagonists); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Entry month:1707
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[Js] Journal subset:IM
[Da] Date of entry for processing:170503
[St] Status:MEDLINE

  3 / 6011 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29468280
[Au] Autor:Erbersdobler A
[Ad] Address:Institut für Pathologie, Universitätsmedizin Rostock, Strempelstraße 14, 18057, Rostock, Deutschland. andreas.erbersdobler@med.uni-rostock.de.
[Ti] Title:Pathologie und histopathologische Begutachtung des Peniskarzinoms. [Pathology and histopathological evaluation of penile cancer].
[So] Source:Urologe A;, 2018 Feb 21.
[Is] ISSN:1433-0563
[Cp] Country of publication:Germany
[La] Language:ger
[Ab] Abstract:BACKGROUND: Penile cancer is rare in Germany and in western European countries. Our understanding of the pathogenesis and pathology of this malignancy has increased considerably in recent years. OBJECTIVES: Clinical management has become more complex, with organ-preserving strategies being increasingly favored. Associated with these developments, the demands on the pathology reports of biopsies and surgical specimens from the penis have also increased. MATERIALS AND METHODS: According to guidelines and the relevant literature, this review outlines the most important aspects that must be considered in the classification and pathological reporting of penile cancer. RESULTS: Correct histological subtyping of penile cancer is important for prognostic and therapeutic considerations. There are also some peculiarities with the current TNM classification system of this tumor compared to other entities. CONCLUSION: Handling of specimens and histopathological typing must be performed by experienced pathologists according to recent developments in the pathogenesis, classification, and therapeutic strategies of penile cancer.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:Publisher
[do] DOI:10.1007/s00120-018-0592-8

  4 / 6011 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27772624
[Au] Autor:Chin-Hong PV
[Ad] Address:Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA. Electronic address: peter.chin-hong@ucsf.edu.
[Ti] Title:Human Papillomavirus in Kidney Transplant Recipients.
[So] Source:Semin Nephrol;36(5):397-404, 2016 09.
[Is] ISSN:1558-4488
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Human papillomavirus (HPV) is a common infection in kidney transplant recipients. HPV causes cervical, anal, vulvar, vaginal, penile and head and neck cancers. Kidney transplant recipients have a disproportionate burden of disease given prolonged immunosuppression. Given the long pre-invasive state of precancer lesions such as cervical intraepithelial neoplasia (CIN) and anal intraepithelial neoplasia (AIN) most HPV-cancers are preventable with screening and targeted treatment of disease. Pre-transplant vaccination of age-eligible kidney transplant recipients is otherwise ideal.
[Mh] MeSH terms primary: Anus Neoplasms/virology
Cervical Intraepithelial Neoplasia/virology
Graft Rejection/prevention & control
Immunosuppressive Agents/adverse effects
Kidney Failure, Chronic/surgery
Kidney Transplantation
Papillomavirus Infections/chemically induced
Uterine Cervical Neoplasms/virology
[Mh] MeSH terms secundary: Anus Neoplasms/diagnosis
Anus Neoplasms/prevention & control
Anus Neoplasms/therapy
Carcinoma in Situ/diagnosis
Carcinoma in Situ/prevention & control
Carcinoma in Situ/therapy
Carcinoma in Situ/virology
Cervical Intraepithelial Neoplasia/diagnosis
Cervical Intraepithelial Neoplasia/prevention & control
Cervical Intraepithelial Neoplasia/therapy
Early Detection of Cancer
Female
Humans
Male
Papanicolaou Test
Papillomaviridae
Papillomavirus Infections/diagnosis
Papillomavirus Infections/prevention & control
Papillomavirus Infections/therapy
Papillomavirus Vaccines/therapeutic use
Uterine Cervical Neoplasms/diagnosis
Uterine Cervical Neoplasms/prevention & control
Uterine Cervical Neoplasms/therapy
Vaginal Smears
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Immunosuppressive Agents); 0 (Papillomavirus Vaccines)
[Em] Entry month:1801
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE

  5 / 6011 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29433986
[Au] Autor:Ottenhof SR; Leone A; Djajadiningrat RS; Azizi M; Zargar K; Kidd LC; Diorio G; Mosiello G; Graafland NM; Spiess PE; Horenblas S
[Ad] Address:Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
[Ti] Title:Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer.
[So] Source:Eur Urol Focus;, 2018 Feb 09.
[Is] ISSN:2405-4569
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BACKGROUND: Treatment of locoregionally advanced penile squamous cell carcinoma (LAPSCC) is challenging. The exact role (in terms of oncological benefit) of extensive surgery is not well established. Moreover, surgery invariably leads to large defects requiring reconstructive surgery. Rectus abdominis myocutaneous (RAM) and abdominal advancement flaps have an independent and constant blood supply, are easily harvested, and provide substantial skin coverage and soft tissue. OBJECTIVE: To determine the surgical and oncological outcomes in patients with LAPSCC undergoing surgical resection with RAM flaps. DESIGN, SETTING, AND PARTICIPANTS: From 2002 to 2016, a multi-institutional database identified 15 LAPSCC patients undergoing flap reconstructions. INTERVENTION: Local surgical resection with RAM or abdominal advancement flap reconstruction. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Perioperative and pathologic data were collected. Postoperative complications were identified using the Clavien-Dindo classification for surgical complications. RESULTS AND LIMITATIONS: Fifteen patients (median age 61 yr) were treated, ten with curative intent. Thirteen patients received induction chemotherapy. Thirteen of the 15 patients (87%) experienced wound complications, including five Clavien-Dindo grade III complications. In 11/15 patients (73%), the disease recurred (median recurrence-free interval 106 d). The majority of recurrences (91%) were locoregional, and in four cases the patient also had lesions in distant organs. Ten of the 15 patients (67%) died of their disease. The overall median follow-up interval was 10.5 mo. The study was limited by its retrospective design, the absence of quality-of-life measurements, and the cohort size. CONCLUSIONS: The results of this study show that surgical resection with reconstruction is associated with a risk of perioperative complications, including high-grade Clavien-Dindo complications. With a cure rate of 27%, surgery must be carefully considered and there is a need for alternative treatments. Lack of robust quality-of-life-data is also a serious shortcoming in the decision process for this patient category. PATIENT SUMMARY: Surgery in locoregionally advanced penile cancer has a low cure rate. Reconstruction of defects is surgically feasible, albeit with a high risk of complications. Furthermore, decision-making lacks robust data on quality of life after surgery.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[St] Status:Publisher

  6 / 6011 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29248557
[Au] Autor:Correa AF; Handorf E; Joshi SS; Geynisman DM; Kutikov A; Chen DY; Uzzo RG; Viterbo R; Greenberg RE; Smaldone MC
[Ad] Address:Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Urology, Creighton University, Omaha, Nebraska. Electronic address: Andres.correa@fccc.edu.
[Ti] Title:Differences in Survival by Receipt of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from NCDB.
[So] Source:J Urol;, 2017 Dec 15.
[Is] ISSN:1527-3792
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: Inguinal lymphadenectomy remains under performed in patients with invasive penile cancer. Using a large national cancer registry we assessed temporal trends in inguinal lymphadenectomy performance and evaluated the impact of the procedure on survival in patients in whom inguinal lymphadenectomy was an absolute indication (T1b-4 N0/x-1) according to NCCN (National Comprehensive Cancer Network®) Guidelines®. MATERIALS AND METHODS: We queried NCDB (National Cancer Database) for all cases of nonmetastatic, T1b-4 N0/X-N1 squamous cell carcinoma of the penis from 2004 to 2014. Multivariable logistic regression models adjusting for patient, demographic and clinicopathological characteristics were used to examine the association between available covariates and receipt of inguinal lymphadenectomy. Cox proportional hazards regression analysis was then done to assess the impact of clinical and pathological variables on overall survival. Propensity score weighted analysis was performed to assess the effect of inguinal lymphadenectomy on overall survival. RESULTS: A total of 2,224 patients met analysis criteria, of whom 606 (27.2%) underwent inguinal lymphadenectomy. Following adjustment the procedure was more likely in younger patients, those who presented with palpable adenopathy (cN1), those treated at an academic facility and those with a more contemporary diagnosis. On survival analysis controlling for all known and measured confounders inguinal lymphadenectomy was associated with improved overall survival (HR 0.79, 95% CI 0.74-0.84, p <0.001). CONCLUSIONS: At hospitals that report to NCDB the overall rate of inguinal lymphadenectomy in patients with invasive penile cancer was only 27.2%. Receipt of inguinal lymphadenectomy was associated with increased overall survival, justifying the procedure as an important quality metric for performance reporting in patients with invasive penile cancer.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180208
[Lr] Last revision date:180208
[St] Status:Publisher

  7 / 6011 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29325693
[Au] Autor:Paner GP; Stadler WM; Hansel DE; Montironi R; Lin DW; Amin MB
[Ad] Address:Department of Pathology, University of Chicago, Chicago, IL, USA; Department of Surgery (Urology), University of Chicago, Chicago, IL, USA. Electronic address: Gladell.Paner@uchospitals.edu.
[Ti] Title:Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.
[So] Source:Eur Urol;, 2018 Jan 08.
[Is] ISSN:1873-7560
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:The Tumor-Node-Metastasis (TNM) classification on cancer staging, jointly developed by the American Joint Commission on Cancer (AJCC) and the Union for International Cancer Control (UICC), has been updated to its 8th edition with two contemporaneous versions published by the AJCC and UICC. While the goal of the AJCC and UICC is to have identical TNM staging systems, differences exist between these two publications including in the staging of urologic cancers. Among several new facets in the AJCC staging manual, a select few of greater import include an expanded section on imaging, presentation of levels of evidence for significant changes, and endorsement of risk assessment models that pass the AJCC quality criteria such as in prostate cancer. The updates for urologic cancers in the AJCC stage categories can be grouped into: (1) newly defined TNM categories and prognostic stage groupings, (2) clarifications and refinements of previously defined categories, and (3) more systematic and expanded presentation of prognostic factors. Changes are harmonized with the current reporting and treatment guidelines. Contributions from genitourinary pathology are evident in the AJCC classification from many of the International Society of Urological Pathology (ISUP) consensus conferences on prostate, kidney, testicular, and penile neoplasms that addressed staging issues and the timely publication of the 4th edition of the World Health Organization (WHO) classification of urinary and male genital organ tumors. New grading approaches for penile (WHO/ISUP grade), prostate (Grade group), and kidney (WHO/ISUP nucleolar grade) cancers were adopted in the AJCC system. Many of these updates in the AJCC staging manual are also included in the 8th UICC TNM edition. In an effort to achieve the optimal staging recommendations for urologic cancers, updates in the 8th TNM edition were generated through the acquisition of best evidences, tapping interdisciplinary resources including consensus recommendations, and enhanced data analysis. PATIENT SUMMARY: In this report, we explain the seminal changes in the 8th edition of the Tumor-Node-Metastasis staging system for urologic cancers. Major stage category definitional changes are in Tumor-Node-Metastasis classifications of testicular, penile, and prostate cancer which improve patient stratification for prognosis and management.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1801
[Cu] Class update date: 180112
[Lr] Last revision date:180112
[St] Status:Publisher

  8 / 6011 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29307685
[Au] Autor:Singh A; Jaipuria J; Goel A; Shah S; Bhardwaj R; Baidya S; Jain J; Jain C; Rawal S
[Ad] Address:Department of Surgical Oncology - Uro-oncology division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini Sector - 5, New Delhi, India - 110085.
[Ti] Title:Comparing outcomes of robotic and open inguinal lymph node dissection in patients with carcinoma penis.
[So] Source:J Urol;, 2018 Jan 04.
[Is] ISSN:1527-3792
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: To compare outcomes between Robot assisted video endoscopic inguinal lymphadenectomy (RA-VEIL) and open inguinal lymph node dissection (OILND) in patients without bulky nodal metastasis in a tandem contemporary cohort. MATERIALS AND METHODS: Prospectively maintained hospital registry of patients undergoing RA-VEIL (51 patients) or OILND (100 patients) from 2012-2016 for groins without bulky nodal metastasis and minimum 9 months follow-up was retrospectively analyzed. Complications were graded by Clavien Dindo classification and nodal yield and disease recurrence on follow up were assessed. Elastic net regression was used to select variables associated with major complications (Clavien ≥3a) for multivariable analysis among plausible factors namely - age, diabetes, body mass index, smoking, nodal stage, surgery type, sartorius transposition, saphenous vein transection and adjuvant radiotherapy. Penalized Likelihood logistic regression methods were used for multivariate analysis to ascertain final effect sizes while accounting for sparse data bias. RESULTS: RA-VEIL and OILND were comparable in median lymph node yield (13 vs 12.5). No patient experienced recurrence on median follow-up of 40 months. RA-VEIL had significantly lower hospital stay, days needing drain in situ, incidence of major complications, edge necrosis, flap necrosis and severe limb oedema. On multivariable analysis, pathological nodal stage [OR 2.8, 95% CI 1.1-6.8, p value 0.027] and OILND [OR 7.5, 95% CI 1.3-43, p value 0.024] emerged as independent risk factors associated with increased hazard of major complications. CONCLUSIONS: RA-VEIL is a feasible technique allowing similar nodal yield while being associated with lower morbidity than OILND in patients without bulky groin adenopathy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180108
[Lr] Last revision date:180108
[St] Status:Publisher

  9 / 6011 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29245259
[Au] Autor:Xiaoqiang L; Xuerong Z; Juan L; Mathew BS; Xiaorong Y; Qin W; Lili L; Yingying Z; Jun L
[Ad] Address:aWest China Hospital, Sichuan University, Chengdu, ChinabDepartment of Anesthesiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen UniversitycDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
[Ti] Title:Efficacy of pudendal nerve block for alleviation of catheter-related bladder discomfort in male patients undergoing lower urinary tract surgeries: A randomized, controlled, double-blind trial.
[So] Source:Medicine (Baltimore);96(49):e8932, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Catheter-related bladder discomfort (CRBD) to an indwelling urinary catheter is defined as a painful urethral discomfort, resistant to conventional opioid therapy, decreasing the quality of postoperative recovery. According to anatomy, the branches of sacral somatic nerves form the afferent nerves of the urethra and bladder triangle, which deriving from the ventral rami of the second to fourth sacral spinal nerves, innervating the urethral muscles and sphincter of the perineum and pelvic floor; as well as providing sensation to the penis and clitoris in males and females, which including the urethra and bladder triangle. Based on this theoretical knowledge, we formed a hypothesis that CRBD could be prevented by pudendal nerve block. OBJECTIVE: To evaluate if bilateral nerve stimulator-guided pudendal nerve block could relieve CRBD through urethra discomfort alleviation. DESIGN AND SETTING: Single-center randomized parallel controlled, double blind trial conducted at West China Hospital, Sichuan University, China. PARTICIPANTS: One hundred and eighty 2 male adult patients under general anesthesia undergoing elective trans-urethral resection of prostate (TURP) or trans-urethral resection of bladder tumor (TURBT). Around 4 out of 182 were excluded, 178 patients were randomly allocated into pudendal and control groups, using computer-generated randomized numbers in a sealed envelope method. A total of 175 patients completed the study. INTERVENTION: Pudendal group received general anesthesia along with nerve-stimulator-guided bilateral pudendal nerve block and control group received general anesthesia only. MAIN OUTCOME MEASURES: Incidence and severity of CRBD; and postoperative VAS score of pain. RESULTS: CRBD incidences were significantly lower in pudendal group at 30 minutes (63% vs 82%, P = .004), 2 hours (64% vs 90%, P < .000), 8 hours (58% vs 79%, P = .003) and 12 hours (52% vs 69%, P = .028) also significantly lower incidence of moderate to severe CRBD in pudendal group at 30 minutes (29% vs 57%, P < .001), 2 hours (22% vs 55%, P < .000), 8 hours (8% vs 27%, P = .001) and 12 hours (6% vs 16%, P = .035) postoperatively. The postoperative pain score in pudendal group was lower at 30 minutes (P = .003), 2 hours (P < .001), 8 hours (P < .001), and 12 hours (P < .001), with lower heart rate and mean blood pressure. One patient complained about weakness in levator ani muscle. CONCLUSION: General anesthesia along with bilateral pudendal nerve block decreased the incidence and severity of CRBD for the first 12 hours postoperatively.
[Mh] MeSH terms primary: Catheters, Indwelling/adverse effects
Nerve Block/methods
Pudendal Nerve
Transurethral Resection of Prostate
Urinary Bladder Neoplasms/surgery
Urinary Catheters/adverse effects
[Mh] MeSH terms secundary: Adult
Aged
Aged, 80 and over
Anesthesia, General
Double-Blind Method
Humans
Male
Middle Aged
Pain Measurement
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Entry month:1712
[Cu] Class update date: 171225
[Lr] Last revision date:171225
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008932

  10 / 6011 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29230263
[Au] Autor:Touzani MA; Yddoussalah O
[Ad] Address:Université Mohammed 5, Faculté de Médecine et de Pharmacie de Rabat, Hopital Ibn Sina, Service d'Urologie B, Maroc.
[Ti] Title:Sarcome de kaposi penien chez un patient seronegatif. [Kaposi's sarcoma of the penis in a HIV-seronegative patient].
[So] Source:Pan Afr Med J;28:61, 2017.
[Is] ISSN:1937-8688
[Cp] Country of publication:Uganda
[La] Language:fre
[Ab] Abstract:Sarcomas of the penis account for less than 5% of all tumors of the penis. They are dominated by Kaposi's sarcoma that mainly affects HIV-positive patients. However, recent studies have shown a relationship between Kaposi's sarcoma and HHV-8 infection (Human herpes virus-8), which explains why this sarcoma occurs in non-immunocompromised and HIV-seronegative patients. We here report the case of a 72-year old patient, with no previous medical history, reporting of gradual onset of tumor-like granulation tissue of 3 years duration at the level of the gland, without secondary location. Given the patient's clinical condition, epidermoid carcinoma or sarcomatoid carcinoma of the penis were suspected. Initial biopsy was negative, the second was in favor of Kaposi's sarcoma, confirmed by immunohistochemistry. The patient underwent chemotherapy.
[Mh] MeSH terms primary: HIV Seronegativity
Penile Neoplasms/diagnosis
Sarcoma, Kaposi/diagnosis
Skin Neoplasms/diagnosis
[Mh] MeSH terms secundary: Aged
Antineoplastic Agents/therapeutic use
Biopsy
Humans
Immunohistochemistry
Male
Penile Neoplasms/drug therapy
Penile Neoplasms/pathology
Sarcoma, Kaposi/drug therapy
Sarcoma, Kaposi/pathology
Skin Neoplasms/drug therapy
Skin Neoplasms/pathology
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents)
[Em] Entry month:1712
[Cu] Class update date: 171222
[Lr] Last revision date:171222
[Js] Journal subset:IM
[Da] Date of entry for processing:171213
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.28.61.13248


page 1 of 602 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information